MedTrace Logo

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

NCT00002456 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2011-11-30

No results posted yet for this study

Summary

RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against normal tissues. Methotrexate and cyclosporine may prevent this from happening.

PURPOSE: Phase III trial to study the effectiveness of treatment with methotrexate and cyclosporine after bone marrow transplantation to provide protection against acute graft-versus-host disease.

Conditions

Interventions

DRUG

cyclosporine

DRUG

methotrexate

PROCEDURE

allogeneic bone marrow transplantation

Sponsors & Collaborators

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Rainer F. Storb, MD · Fred Hutchinson Cancer Center

Study Design

Purpose
SUPPORTIVE_CARE

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1986-05-31
Completion
2002-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002456 on ClinicalTrials.gov